New MRI Techniques for Diagnosis and Treatment of Patients With Abdominal Aortic Aneurysms

Completed

• Conditions: Abdominal Aortic Aneurysm Without Rupture

• Registration Number: NCT05976711
• Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary

An abdominal aortic aneurysm (AAA) is a pathological dilatation of the aorta in the belly which can rupture leading to bleeding within the belly. To prevent rupture elective surgery can be performed. Endovascular repair (EVAR) is a surgical intervention whereby a stent is inserted into the AAA to prevent it from further growth and rupture.

Standard AAA management has several drawbacks. To start: maximum AAA diameter is used to determine upon timing of elective repair but is imprecise in predicting the risk of rupture resulting in an unmet clinical need. Secondly, EVAR outcome and complication occurrence remain unpredictable due to poor prediction ability of computed tomography (CT) and ultrasound (US) utilised in the follow-up protocol. Lastly, patients and physicians are being repeatedly exposed to cumulative radiation toxicity. All these drawbacks could be solved by trading the standard imaging modalities by magnetic resonance imaging (MRI). Within the MARVY, advanced MRI techniques are used to find out if standard imaging techniques could be replaced by MRI in three phases of the AAA management (surveillance, surgery planning and post-operative follow-up). The two most important MRI techniques that will be used are 4D flow MRI and dynamic contrast enhanced (DCE) MRI which give respectively information about the blood flow within the AAA and perfusion of the aortic wall.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-04
• Study First Submitted: 2023-07-26
• Study First Submitted QC: 2023-07-26
• Study First Posted: 2023-08-04
• Primary Completion: 2025-03-13
• Status Verified: 2025-04
• Study Completion: 2025-06-12
• Last Update Submitted: 2025-07-10
• Last Update Posted: 2025-07-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• diagnosed with AAA
• provision of written informed consent

Inclusion Criteria for surveillance part:

• maximum AAA diameter between 3-5 cm
• not scheduled for aneurysm repair at the time of inclusion

Inclusion Criteria for planning part:

• planned for elective EVAR

Inclusion Criteria for follow-up part:

• ten complication free years after EVAR or sac regression after EVAR; or
• type I endoleak after EVAR; or
• type II endoleak after EVAR;

Exclusion Criteria

• Supra- or pararenal AAA
• Inflammatory, infectious or mycotic AAA
• Vasculitis and connective tissue disease
• Patients that underwent open surgical repair for their AAA
• Patients with ruptured AAAs
• Patients that previously presented with allergic reactions to intravenous contrast agents

Exclusion Criteria for surveillance part:

• previous AAA repair
• severely reduced renal function
• previous allergic reactions to intravenous contrast agents

Exclusion Criteria for planning part:

• previous AAA repair

Exclusion Criteria for follow-up part:

• severely reduced renal function
• previous allergic reactions to intravenous contrast agents

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
EVAR planning: correlation between morphological parameters measured based on MRA and CTA	half year	The main study parameter for phase B2 (EVAR planning) is the difference between anatomical measurements (lengths and diameters) based on both CTA and MRA. Several quantitative anatomical measurements will be utilised to assess the feasibility of MRA for planning of EVARs.
EVAR follow up: difference in MRI parameters between patients with endoleaks and without	1 year	The main study parameter for phase B3 (EVAR follow-up) is the difference in MRI parameters measured post-operatively in patients with and without EVAR related complications.
Surveillance: correlation between growth rate and MRI derived parameters	1 year	The main study parameter for phase B1 (surveillance) is the correlation between growth rate of the AAA (determinant for the standard of care) and measured MRI parameters acquired with 4D flow MRI and DCE-MRI.

Trial Locations

Locations (1)

Amsterdam UMC; 🇳🇱 Amsterdam, Noord-Holland, Netherlands